用于肺结核病管理的可气溶性皮拉津胺载荷生物降解纳米粒子
Komal Parmar1, Swati Sondarva1
1Department of Pharmaceutics, ROFEL Shri G.M. Bilakhia College of Pharmacy, Vapi, Gujarat, India.
Journal of aerosol medicine and pulmonary drug delivery
|January 10, 2024
概括
可生物降解的聚合物纳米粒子 (PNPs) 为结核病治疗提供了改善的肺部输送pyrazinamide. 这种干粉吸入器配方证明了药物沉积和稳定性的增强,为有效的肺部输送提供了稳定.
科学领域:
- 制药科学 制药科学
- 纳米技术 纳米技术
- 肺部药物输送 肺部药物输送
背景情况:
- 皮拉津胺是治疗活跃结核病的关键III类抗生素.
- 肺部注射旨在提供有针对性的输送和减少全身副作用.
- 可生物降解的聚合物纳米粒子 (PNPs) 提供了增强药物递送的潜力.
研究的目的:
- 开发和优化用于干粉吸入器配方的pyrazinamide载荷PNP.
- 评估PNP的物理化学,气溶和体内性能.
- 评估开发的肺药物输送系统的稳定性.
主要方法:
- 双乳液溶剂蒸发技术用于PNP制剂.
- 设计实验以优化配方的设计.
- 粒子大小的表征,捕获效率,多分散性指数,泽塔潜力和体外药物释放.
- 评估气溶性能,体内沉积和稳定性.
主要成果:
- 优化PNP的颗粒大小为284.5nm,捕获效率为71.82%,在4小时内体外药物释放率为79.01%.
- 质量中介气动直径适合膜沉积 (2,910微米).
- 在体内研究表明,药物在气管和肺部的沉积增加,气膜巨细胞的吸收率更高.
结论:
- 可生物降解的聚合物纳米颗粒提供了一个有效的肺药物递送系统为pyrazinamide.
- 开发的干粉吸入器配方表现出良好的稳定性和增强的体内性能.
- 通过直接肺部注射,PNPs代表了结核病治疗的有希望的方法.
相关概念视频
Pulmonary Tuberculosis V
180
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
180
Pulmonary Tuberculosis I
243
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
243
Pulmonary Tuberculosis II
239
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
239
Inhaled Medications
271
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
271


